An unconventional FDA panel is assessing the safety and efficacy of previously-banned peptides. It could open up a multibillion-dollar market.
Inside the unconventional FDA panel that could reshape the peptide industry
By
Hilary Brueck
You're currently following this author!
Want to unfollow? Unsubscribe via the link in your email.
The Food and Drug Administration is meeting next month to consider easing restrictions on several peptides, a group of unapproved…
Several popular peptide injections have been praised by Health Secretary Robert F. Kennedy Jr.
When U.S. health officials meet next month to reconsider a list of controversial peptide drugs, they will hear from a new set of…
Peptide drugs are popular, but FDA scientists warn they're untested, may be harmful.
FDA scientists found only rat data on the seven peptides Kennedy's panel votes on this week — and seven advisers sell the…
FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than…
